

**BETH C. DRAIN, CA CSR NO. 7152**

BEFORE THE  
INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE AND THE  
APPLICATION REVIEW SUBCOMMITTEE  
TO THE  
CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE  
ORGANIZED PURSUANT TO THE  
CALIFORNIA STEM CELL RESEARCH AND CURES ACT  
EMERGENCY MEETING

LOCATION: VIA ZOOM

DATE: FRIDAY, JULY 10, 2020  
3 P.M.

REPORTER: BETH C. DRAIN, CA CSR  
CSR. NO. 7152

FILE NO.: 2020-15

I N D E X

ITEM DESCRIPTION	PAGE NO.
<b>OPEN SESSION:</b>	
1. CALL TO ORDER	3
2. ROLL CALL	3
3. CONSIDERATION OF EXISTENCE OF EMERGENCY SITUATION. EMERGENCY SITUATION MEANS ANY OF THE FOLLOWING AS DETERMINED BY A MAJORITY OF THE MEMBERS OF THE INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE: (A) WORK STOPPAGE OR OTHER ACTIVITY THAT SEVERELY IMPACTS PUBLIC HEALTH OR SAFETY OR BOTH; (B) CRIPPLING DISASTER THAT SEVERELY IMPAIRS PUBLIC HEALTH OR SAFETY OR BOTH.	5
4. CONSIDERATON OF SUPPLEMENTAL FUNDING FOR EXISTING CLIN2 COVID-19 GRANTS.	8
5. CONSIDERATION OF APPLICATIONS SUBMITTED IN RESPONSE TO SPECIAL CALL FOR COVID-19 PROJECTS.	14
<b>CLOSED SESSON:</b>	<b>NONE</b>
6. DISCUSSION OF CONFIDENTIAL INTELLECTUAL PROPERTY OR WORK PRODUCT, PREPUBLICATION DATA, FINANCIAL INFORMATION, CONFIDENTIAL SCIENTIFIC RESEARCH OR DATA, AND OTHER PROPRIETARY INFORMATION RELATING TO	

**BETH C. DRAIN, CA CSR NO. 7152**

APPLICATIONS SUBMITTED IN RESPONSE TO AGENDA ITEM 4 ABOVE. (HEALTH AND SAFETY CODE 125290.30(F)(3)(B) AND (C)).

**DISCUSSION ITEMS:**

- |                   |      |
|-------------------|------|
| 7. PUBLIC COMMENT | NONE |
| 8. ADJOURNMENT    | 27   |

**BETH C. DRAIN, CA CSR NO. 7152**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

JULY 10, 2020; 3 P.M.

CHAIRMAN THOMAS: THANK YOU, MARIA. LIKE TO WELCOME EVERYBODY TO THE JULY 10TH, 2020, MEETING OF THE ICOC -- EMERGENCY MEETING, I SHOULD SAY -- OF THE ICOC AND APPLICATION REVIEW SUBCOMMITTEE. MARIA, WILL YOU PLEASE CALL THE ROLL.

MS. BONNEVILLE: ANNE-MARIE DULIEGE.

DR. DULIEGE: HERE.

MS. BONNEVILLE: YSABEL DURON.

MS. DURON: YES.

MS. BONNEVILLE: DAVID HIGGINS.

DR. HIGGINS: YES.

MS. BONNEVILLE: STEVE JUELSGAARD.

MR. JUELSGAARD: HERE.

MS. BONNEVILLE: DAVE MARTIN. LET ME LOK FOR DAVE. I KNOW HE'S HERE. DAVE, YOU ARE UNMUTED, BUT WE CANNOT HEAR YOU OR SEE YOU. SO I'M GOING TO GO ON WITH ROLL CALL AND COME BACK.

LAUREN MILLER-ROGEN.

MS. MILLER-ROGEN: HERE.

MS. BONNEVILLE: ADRIANA PADILLA. JOE PANETTA.

MR. PANETTA: YES.

MS. BONNEVILLE: FRANCISCO PRIETO.

**BETH C. DRAIN, CA CSR NO. 7152**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

DR. PRIETO: HERE.

MS. BONNEVILLE: ROBERT QUINT.

DR. QUINT: PRESENT.

MS. BONNEVILLE: AL ROWLETT.

MR. ROWLETT: HERE.

MS. BONNEVILLE: JEFF SHEEHY.

MR. SHEEHY: HERE.

MS. BONNEVILLE: OS STEWARD.

DR. STEWARD: HERE.

MS. BONNEVILLE: JONATHAN THOMAS.

CHAIRMAN THOMAS: HERE.

MS. BONNEVILLE: ART TORRES.

MR. TORRES: HERE.

MS. BONNEVILLE: DIANE WINOKUR.

MS. WINOKUR: HERE.

MS. BONNEVILLE: AND DAVID MARTIN. OKAY.

DAVE? NOPE. CAN'T HEAR; CAN'T SEE. OKAY. WE WILL GO ON.

CHAIRMAN THOMAS: THANK YOU, MARIA. GOING TO MOVE RIGHT TO THE ACTION ITEMS. AS HAS BEEN THE CASE WITH ALL OF THESE COVID ROUND MEETINGS, THE FIRST ACTION ITEM IS CONSIDERATION OF EXISTENCE OF EMERGENCY SITUATION. THE EMERGENCY SITUATION MEANS ANY OF THE FOLLOWING AS DETERMINED BY A MAJORITY OF THE MEMBERS OF THE ICOC: A, WORK STOPPAGE OF ANY

**BETH C. DRAIN, CA CSR NO. 7152**

1 ACTIVITY THAT SEVERELY IMPACTS PUBLIC HEALTH OR  
2 SAFETY OR BOTH; OR B, CRIPPLING DISASTER THAT  
3 SEVERELY IMPAIRS PUBLIC HEALTH OR SAFETY OR BOTH.

4 DO I HEAR A MOTION TO APPROVE?

5 DR. STEWARD: SO MOVED.

6 MS. DURON: YSABEL SECONDS.

7 CHAIRMAN THOMAS: MOVED BY DR. STEWARD,  
8 SECONDED BY MS. DURON. IS THERE ANY DISCUSSION ON  
9 THIS ITEM? ANY COMMENTS FROM MEMBERS OF THE PUBLIC?  
10 HEARING NONE, MARIA, WILL YOU PLEASE CALL THE ROLL.

11 MS. BONNEVILLE: ANNE-MARIE DULIEGE.

12 DR. DULIEGE: YES.

13 MS. BONNEVILLE: YSABEL DURON.

14 MS. DURON: YES.

15 MS. BONNEVILLE: DAVID HIGGINS.

16 DR. HIGGINS: YES.

17 MS. BONNEVILLE: STEVE JUELSGAARD.

18 MR. JUELSGAARD: YES.

19 MS. BONNEVILLE: DAVE MARTIN. WE CAN'T  
20 HEAR YOU, BUT I SEE YOUR THUMB.

21 DR. MARTIN: (THUMB UP.)

22 MS. BONNEVILLE: LAUREN MILLER-ROGEN.

23 MS. MILLER-ROGEN: YES.

24 MS. BONNEVILLE: ADRIANA PADILLA. JOE  
25 PANETTA.

**BETH C. DRAIN, CA CSR NO. 7152**

1 MR. PANETTA: YES.  
2 MS. BONNEVILLE: FRANCISCO PRIETO.  
3 DR. PRIETO: AYE.  
4 MS. BONNEVILLE: ROBERT QUINT.  
5 DR. QUINT: YES.  
6 MS. BONNEVILLE: AL ROWLETT.  
7 MR. ROWLETT: YES.  
8 MS. BONNEVILLE: JEFF SHEEHY.  
9 MR. SHEEHY: YES.  
10 MS. BONNEVILLE: OS STEWARD.  
11 DR. STEWARD: YES.  
12 MS. BONNEVILLE: JONATHAN THOMAS.  
13 CHAIRMAN THOMAS: YES.  
14 MS. BONNEVILLE: ART TORRES.  
15 MR. TORRES: AYE.  
16 MS. BONNEVILLE: DIANE WINOKUR.  
17 MS. WINOKUR: YES.  
18 MS. BONNEVILLE: THANK YOU. MOTION  
19 CARRIES.  
20 CHAIRMAN THOMAS: THANK YOU. GOING TO  
21 PROCEED NOW TO THE PROCEEDINGS OF THE APPLICATION  
22 REVIEW SUBCOMMITTEE WHICH IS GOING TO BE LED TODAY  
23 AND GOING FORWARD BY DR. STEWARD. AS IT HAPPENS,  
24 DR. STEWARD IS CONFLICTED OUT OF THE FIRST ITEM, SO  
25 I'M GOING TO RUN THIS PARTICULAR ITEM AND THEN TURN

**BETH C. DRAIN, CA CSR NO. 7152**

1 IT OVER TO HIM.

2 MR. TORRES: WHAT HAPPENED TO MR. SHEEHY?  
3 HE'S NOT RUNNING THESE THINGS ANYMORE?

4 CHAIRMAN THOMAS: MR. SHEEHY IS NOT GOING  
5 TO BE RUNNING THE APPLICATION REVIEW SUBCOMMITTEE.

6 MR. TORRES: SORRY TO HEAR THAT.

7 CHAIRMAN THOMAS: SO ANY OTHER COMMENTS  
8 FROM MEMBERS OF THE BOARD?

9 LET'S MOVE TO ITEM 4, CONSIDERATION OF  
10 SUPPLEMENTAL FUNDING FOR EXISTING CLIN COVID AWARD  
11 GRANTS AND SPECIFICALLY LOOKING AT CLIN2 COVID  
12 11775. DR. CREASEY IS GOING TO BE LEADING THE  
13 DISCUSSION ON THIS ITEM. DR. CREASEY, WOULD YOU  
14 PLEASE TAKE IT FROM HERE?

15 DR. CREASEY: THANK YOU, CHAIRMAN THOMAS.  
16 DEAR CIRM AND BOARD MEMBERS, I'M HERE BEFORE YOU TO  
17 PRESENT SUPPLEMENTAL FUNDING FOR AN ACTIVE COVID-19  
18 CLINICAL TRIAL AWARD. THIS IS A SUPPLEMENT TO AN  
19 ACTIVE AWARD THAT WAS AWARDED TO DR. JOHN ZAIA WITH  
20 THE CITY OF HOPE, AGAIN, FOR COLLECTION OF  
21 CONVALESCENT PLASMA AND THEN UTILIZING THAT  
22 CONVALESCENT PLASMA TO TREAT PATIENTS.

23 SO JUST TO REMIND YOU ALL THAT  
24 CONVALESCENT PLASMA, YOU HAVE APPROVED IT AS A VITAL  
25 RESEARCH OPPORTUNITY. SO THE NEXT COUPLE SLIDES ARE

**BETH C. DRAIN, CA CSR NO. 7152**

1 REALLY JUST GOING TO BE REMINDERS FOR WHAT YOU HAVE  
2 GUIDED US TO DO. SO CONVALESCENT PLASMA IS VITAL  
3 RESEARCH OPPORTUNITY PER PROPOSITION 71.

4 AND THAT THE BOARD IS ALLOWING  
5 SUPPLEMENTAL FUNDING FOR ACTIVE COVID-19 CLINICAL  
6 TRIAL AWARDS TO EXPAND THIS EFFORT. DR. ZAIA WAS  
7 KIND ENOUGH TO PUT TOGETHER A LETTER THAT WAS  
8 INCLUDED FOR YOUR CONSIDERATION LAST NIGHT. I HOPE  
9 YOU HAD THE CHANCE TO REVIEW IT.

10 JUST TO REMIND YOU AGAIN WHAT SUPPLEMENTAL  
11 FUNDING FOR CLINICAL TRIAL PROJECTS MEANS IS, AGAIN,  
12 THE SUPPLEMENT CANNOT EXCEED 250,000 AND THOSE FUNDS  
13 TO BE BROUGHT -- FUNDING REQUESTS FOR THE  
14 SUPPLEMENTS ARE TO COME BEFORE THE GOVERNING BOARD'S  
15 APPLICATION REVIEW SUBCOMMITTEE.

16 THE CIRM TEAM WAS PROVIDED WITH A DETAILED  
17 PROPOSAL BY DR. ZAIA, AND WE REVIEWED IT AND WE  
18 HIGHLY RECOMMEND IT FOR THE BOARD TO CONSIDER  
19 FUNDING THIS SUPPLEMENT.

20 CHAIRMAN THOMAS: THANK YOU, DR. CREASEY.

21 DR. CREASEY: I'M NOT THROUGH YET. I  
22 WANTED TO ACCENTUATE THAT BOTH THE ACTIVE AWARD AS  
23 WELL AS THE SUPPLEMENT ARE REALLY OUTREACHING TO THE  
24 UNDERSERVED POPULATIONS.

25 AND THE LAST SLIDE IS JUST EXPLAINING THE

**BETH C. DRAIN, CA CSR NO. 7152**

1 NEED FOR THE SUPPLEMENT REALLY IS FOR COLLECTING  
2 PLASMA AND TREATING DUE TO THE RECENT SURGE IN THE  
3 UNDERSERVED COMMUNITIES IN SOUTHERN CALIFORNIA. AND  
4 I'M SURE YOU ARE WELL AWARE OF THAT. SO I'M THROUGH  
5 NOW. THANK YOU.

6 CHAIRMAN THOMAS: THANK YOU VERY MUCH, DR.  
7 CREASEY.

8 DO WE HAVE A MOTION TO APPROVE THE  
9 \$250,000 SUPPLEMENTAL AWARD FOR DR. ZAIA'S PROJECT?

10 DR. HIGGINS: SO MOVED.

11 DR. DULIEGE: I SECOND.

12 MS. BONNEVILLE: I GOT THE SECOND. WHO  
13 WAS THE FIRST?

14 CHAIRMAN THOMAS: DR. HIGGINS.

15 DR. HIGGINS: DAVID HIGGINS, YES.

16 CHAIRMAN THOMAS: IS THERE DISCUSSION BY  
17 MEMBERS OF THE BOARD? YES. DAVID.

18 DR. HIGGINS: I HAVE JUST A QUICK  
19 QUESTION, REALLY A SCIENTIFIC QUESTION. THERE'S  
20 BEEN A LOT OF CONVALESCENT WORK IN THE MEDIA THE  
21 LAST COUPLE DAYS. HOW DOES THIS RELATE TO THAT? IS  
22 IT THE SAME AS? IS IT DIFFERENT THAN? IS IT  
23 MORE --

24 DR. CREASEY: DR. ZAIA IS ON THE PHONE,  
25 AND HE MIGHT WANT TO ANSWER THAT, BUT I CAN START BY

**BETH C. DRAIN, CA CSR NO. 7152**

1 SAYING IT'S, AGAIN, VERY SIMILAR. DR. ZAIA'S WORK  
2 IS CONNECTED WITH THE MAYO CLINIC AND THE NATIONAL  
3 EFFORT PROVIDING CONVALESCENT PLASMA. AND WHAT'S  
4 GREAT IS THAT WE'RE ALSO CONNECTED TO JOHN HOPKINS.  
5 SO THE WHOLE EFFORT IS TOWARDS IDENTIFYING, PER FDA  
6 GUIDELINES, THE CONVALESCENT PLASMA WITH SPECIFIC  
7 TITERS THAT WOULD ALLOW THEN FOR ADMINISTERING THEM  
8 TO PATIENTS WITH UNMET MEDICAL NEEDS WHO ON HAVE  
9 CONVALESCENT PLASMA.

10 DR. HIGGINS: THANK YOU.

11 MS. DURON: NO. NO. NO. I WAS JUST  
12 WONDERING IF DR. ZAIA IS ON THE PHONE.

13 MS. BONNEVILLE: I DON'T SEE HIM ON THE  
14 CALL.

15 DR. CREASEY: OKAY.

16 MS. BONNEVILLE: I THINK YSABEL HAD A  
17 QUESTION.

18 MS. DURON: NO. I ACTUALLY HAD A COMMENT.  
19 I'LL THRILLED TO SEE THE LETTER THAT CAME THROUGH  
20 AND PARTICULARLY EXCITED, ONE, THAT YOU HAVE TAKEN  
21 THIS TO HEART, THAT YOU'RE GOING TO BE LOOKING --  
22 WORKING HAVE JUDICIOUSLY WITH THESE DIFFERENT  
23 CLINICS THROUGHOUT SOUTHERN CALIFORNIA, WHICH HAS  
24 BEEN EXTRAORDINARILY HEAVILY HIT IN THE COMMUNITIES,  
25 RACIAL AND ETHNIC COMMUNITIES, AND I'M ALSO GLAD TO

**BETH C. DRAIN, CA CSR NO. 7152**

1 SEE AN INCLUSION OF WORK WITH NATIVE AMERICANS.  
2 THAT IS REALLY EXCITING TO SEE. SO THANK YOU VERY  
3 MUCH FOR TAKING THIS TO HEART. I REALLY APPRECIATE  
4 IT. THANK YOU.

5 DR. CREASEY: THANK YOU FOR YOUR CONTINUED  
6 SUPPORT, AND THANK YOU ALSO FOR THE UNIVERSITY OF  
7 CALIFORNIA IRVINE FOR HELPING DR. ZAIA AND  
8 ACCOMPLISHING THIS GOAL.

9 MR. TORRES: YAY, IRVINE.

10 CHAIRMAN THOMAS: ANY OTHER DISCUSSION BY  
11 MEMBERS OF THE BOARD? ANY COMMENTS BY MEMBERS OF  
12 THE PUBLIC?

13 DR. MILLAN: I THINK DAVID HIGGINS, J.T.,  
14 HAS HIS HAND UP.

15 DR. HIGGINS: I WAS ON MUTE. SORRY. I  
16 JUST WANTED TO REITERATE MY THANKS TO DR. DURON AND  
17 HER LEADERSHIP, WHICH, WITHOUT GOING INTO TOO MUCH  
18 DETAIL, I THINK I'M GUILTY OF THE I DON'T THINK I'M  
19 A RACIST, BUT IF I DON'T DO SOMETHING ABOUT IT, I AM  
20 KIND OF THING. AND I THINK SHE'S LED THE WAY FOR ME  
21 ON THAT FRONT, AND I REALLY APPRECIATE THAT.

22 MS. DURON: THANK YOU, DAVID, FOR THE  
23 HONORARY DEGREE.

24 DR. HIGGINS: VERY EASY TO COME BY.

25 MS. DURON: I AM A HEARTFELT JOURNALIST.

**BETH C. DRAIN, CA CSR NO. 7152**

1 THAT'S WHAT I AM.

2 MR. TORRES: I'LL HAVE TO WORK ON THAT  
3 HONORARY DEGREE FROM UC.

4 MS. DURON: THANK YOU. THANK YOU.

5 CHAIRMAN THOMAS: ANY OTHER COMMENTS BY  
6 MEMBERS OF THE BOARD? HEARING NONE, AND HAVING  
7 HEARD NO COMMENTS FROM MEMBERS OF THE PUBLIC, MARIA,  
8 WILL YOU PLEASE CALL THE ROLL.

9 MS. BONNEVILLE: ANNE-MARIE DULIEGE.

10 DR. DULIEGE: YES.

11 MS. BONNEVILLE: YSABEL DURON.

12 MS. DURON: YES.

13 MS. BONNEVILLE: DAVID HIGGINS.

14 DR. HIGGINS: YES.

15 MS. BONNEVILLE: STEVE JUELSGAARD.

16 MR. JUELSGAARD: YES.

17 MS. BONNEVILLE: DAVE MARTIN. YES? I SAW  
18 THE YES AND THE THUMB UP. OKAY. THANK YOU.

19 DR. MARTIN: (THUMB UP.)

20 MS. BONNEVILLE: LAUREN MILLER-ROGEN.

21 MS. MILLER-ROGEN: YES.

22 MS. BONNEVILLE: ADRIANA PADILLA. JOE  
23 PANETTA.

24 MR. PANETTA: YES.

25 MS. BONNEVILLE: FRANCISCO PRIETO.

**BETH C. DRAIN, CA CSR NO. 7152**

1 DR. PRIETO: AYE.  
2 MS. BONNEVILLE: ROBERT QUINT.  
3 DR. QUINT: YES.  
4 MS. BONNEVILLE: AL ROWLETT.  
5 MR. ROWLETT: YES.  
6 MS. BONNEVILLE: JEFF SHEEHY.  
7 MR. SHEEHY: YES.  
8 MS. BONNEVILLE: JONATHAN THOMAS.  
9 CHAIRMAN THOMAS: YES.  
10 MS. BONNEVILLE: ART TORRES.  
11 MR. TORRES: AYE.  
12 MS. BONNEVILLE: DIANE WINOKUR.  
13 MS. WINOKUR: YES.  
14 MS. BONNEVILLE: MOTION CARRIES.  
15 CHAIRMAN THOMAS: OKAY. IS OS BACK ON AT  
16 THIS POINT?  
17 MS. BONNEVILLE: HE'S ON, YES.  
18 CHAIRMAN THOMAS: OS, WE'RE ON TO ITEM NO.  
19 5, PLEASE. IF YOU COULD TAKE IT FROM HERE.  
20 DR. STEWARD: THANK YOU, CHAIRMAN THOMAS.  
21 AND I'LL TRY VERY HARD TO FOLLOW IN JEFF'S EXCELLENT  
22 FOOTSTEPS OVER THE YEARS IN CHAIRING THESE SESSIONS.  
23 SO UNDER CONSIDERATION TODAY ARE THE  
24 APPLICATIONS THAT WERE REVIEWED BY THE GRANTS  
25 WORKING GROUP A COUPLE WEEKS AGO, I GUESS. WOULD IT

**BETH C. DRAIN, CA CSR NO. 7152**

1 BE POSSIBLE TO PUT UP THE LIST SO WE CAN VIEW THIS?

2 MS. BONNEVILLE: OS, GIL HAS A  
3 PRESENTATION TO GO THROUGH.

4 DR. STEWARD: WILL IT END WITH THE LIST OF  
5 APPLICATIONS AND THE SUMMARIES? TERRIFIC. THANK  
6 YOU, GIL. YOU'RE ON.

7 DR. SAMBRANO: THANK YOU, OS. DOUG, IF  
8 YOU COULD PUT UP THE PRESENTATION, I'LL QUICKLY GO  
9 THROUGH THAT.

10 GOOD AFTERNOON, EVERYONE. SO, ONCE AGAIN,  
11 WE ARE LOOKING AT THE COVID-19 PROGRAM SUBMISSIONS  
12 FOR THIS SIXTH CYCLE NOW OF THE PROGRAM. WE HAVE,  
13 AS YOU KNOW, A SPECTRUM OF APPLICATION TYPES THAT  
14 COME THROUGH. THIS PARTICULAR REVIEW, WE HAD A  
15 COUPLE OF DISC1 APPLICATIONS, ONE CLIN1 APPLICATION,  
16 AND SEVERAL DISC2 APPLICATIONS.

17 AND ON THE NEXT SLIDE YOU CAN SEE THE  
18 TABLE THAT SHOWS THE RESPECTIVE AWARD AMOUNTS AND  
19 AWARD DURATIONS FOR THESE DIFFERENT TYPES OF AWARDS.  
20 AND THE TWO THAT ARE RECOMMENDED, ONE OF THEM IS A  
21 DISC1, THE OTHER ONE IS A DISC2. AND SO YOU CAN GO  
22 ON TO THE NEXT SLIDE. THANK YOU.

23 SO ONE OF THE THINGS THAT WE CONTINUE TO  
24 DO THAT WE IMPLEMENTED IN THE LAST COUPLE OF CYCLES  
25 IS ENSURING THAT APPLICANTS ARE ADDRESSING THE NEEDS

**BETH C. DRAIN, CA CSR NO. 7152**

1 OF THE UNDERSERVED. AND SO WE HAVE DONE THAT IN A  
2 COUPLE OF WAYS. ONE IS THAT IN THE CLIN2 PROJECTS,  
3 WE REQUIRE THAT ALL CLINICAL TRIAL PROPOSALS INCLUDE  
4 A PLAN FOR OUTREACH AND INCLUSION OF MINORITY AND  
5 UNDERSERVED POPULATIONS IN THEIR STUDIES. AND THEN  
6 WITH ALL OTHER APPLICATIONS, WE WANT TO KNOW FROM  
7 THE APPLICANTS HOW IT IS THAT THEIR OVERALL STUDY  
8 PLAN AND DESIGN HAS CONSIDERED SPECIFICALLY THE  
9 DISPROPORTIONAL IMPACT OF COVID-19 ON THOSE  
10 POPULATIONS. AND SO THESE ARE ELEMENTS THAT ARE  
11 LOOKED AT AND CONSIDERED BY THE REVIEW PANEL. AND  
12 SO YOU WILL SEE SOMETIMES COMMENTS RELATED TO THIS.  
13 AND SO IT HAS BECOME A COMPONENT OF THE REVIEW.

14 WE ARE DOING THIS STILL AS A PILOT WITH US  
15 STILL TRYING TO FIGURE OUT HOW BEST TO IMPLEMENT  
16 THIS, BUT I THINK OVERALL IT'S BEEN A GREAT  
17 ADDITION.

18 ALL RIGHT. SO THEN IN TERMS OF THE  
19 SPECIFIC RECOMMENDATIONS, WE HAD EIGHT APPLICATIONS  
20 THAT WERE REVIEWED. TWO ARE RECOMMENDED, AS  
21 MENTIONED. ONE IS A DISC1 AND THE OTHER DISC2. THE  
22 FUNDS AVAILABLE, GIVEN THE LAST ITEM WE HAD, IS NOW  
23 REDUCED TO 672,000. THE TOTAL APPLICANT REQUEST IS  
24 JUST ABOUT 400,000 TO COVER THOSE TWO APPLICATIONS.

25 THE NEXT SLIDE PLEASE. AND SO THESE ARE

**BETH C. DRAIN, CA CSR NO. 7152**

1 THE TWO PROPOSALS. THE FIRST ONE IS A DISC1  
2 PROPOSAL THAT GOT A SCORE OF 90. THAT ONE IS  
3 ENTITLED "DEVELOPMENT OF ANTI-COVID RNAI  
4 THERAPEUTICS USING HUMAN IPSC-DERIVED ALVEOLAR  
5 EPITHELIAL CELLS." SO THIS PROJECT IS ONE THAT  
6 WOULD DEVELOP A METHOD FOR INTRODUCING RNAI  
7 BIOLOGICS AND AS A POTENTIAL THERAPY TO TREAT OR  
8 PREVENT COVID-19. AND THEY'RE REQUESTING A HUNDRED  
9 FIFTY THOUSAND.

10 THE SECOND APPLICATION THAT'S RECOMMENDED  
11 IS A DISCOVERY 2 APPLICATION. SO THIS IS ONE THAT  
12 WOULD BE SEEKING TO IDENTIFY A THERAPEUTIC  
13 CANDIDATE, AND THIS ALSO SCORED A 90. AND WHAT THIS  
14 IS IS A SCREEN OF SOME FDA-APPROVED DRUGS USING A  
15 STEM CELL-BASED LUNG ORGANOID MODEL. SO THIS IS ONE  
16 THAT WOULD ALLOW THEM TO ASSESS THE ACTIVITY OF TWO  
17 DRUG CANDIDATES AND THEIR CAPABILITY OF PROMOTING OR  
18 PREVENTING, INFECTIVITY IN LUNG ORGANOID CELLS AND  
19 LOOKING AT OTHER VARIOUS PARAMETERS IN THOSE LUNG  
20 ORGANOID FOR THOSE EFFECTS. AND IF SUCCESSFUL,  
21 THEY COULD TAKE ONE OR BOTH OF THESE CANDIDATES  
22 FORWARD DEPENDING ON THOSE FINDINGS.

23 AND SO THE APPLICANT IS REQUESTING  
24 249,999, SO JUST ABOUT 250,000. SO THOSE ARE THE  
25 TWO APPLICATIONS THAT RECOMMENDED.

**BETH C. DRAIN, CA CSR NO. 7152**

1 DOUG, YOU CAN PUT UP THE SPREADSHEET THAT  
2 HAS ALL THE OTHER APPLICATIONS ON IT FOR EVERYONE TO  
3 SEE. AND THAT CONCLUDES MY PRESENTATION. DR.  
4 STEWARD.

5 DR. STEWARD: THANK YOU, GIL. SO  
6 FOLLOWING OUR USUAL ORDER OF GO IN OUR CONSIDERATION  
7 HERE, THE FIRST ITEM IS WHETHER ANYONE ON THE BOARD  
8 HAS AN APPLICATION THAT THEY WOULD LIKE TO RECOMMEND  
9 FOR MOVING FROM TIER II TO TIER I.

10 MS. BONNEVILLE: DOUG, CAN YOU GET THE  
11 SPREADSHEET UP WHEN YOU GET A MINUTE?

12 DR. STEWARD: I AM NOT SEEING ANY HANDS,  
13 ARE YOU, MARIA?

14 MS. BONNEVILLE: LET'S SEE. NOPE. I DO  
15 NOT SEE ANY.

16 DR. STEWARD: GOING ONCE; GOING TWICE.  
17 DOES ANYONE HAVE APPLICATIONS THAT THEY WOULD LIKE  
18 TO MOVE FROM TIER I TO TIER II? AGAIN, I'M NOT  
19 SEEING ANY HANDS. OKAY. EXCELLENT.

20 SO CAN WE HAVE A MOTION? AND LET'S START  
21 WITH THE ONES THAT WE DON'T WANT TO FUND, NT TO FUND  
22 APPLICATIONS IN TIER II.

23 DR. PRIETO: SO MOVED.

24 DR. STEWARD: I THINK THAT WAS FRANCISCO.

25 DR. PRIETO: YES.

**BETH C. DRAIN, CA CSR NO. 7152**

1 DR. HIGGINS: SECOND.

2 DR. STEWARD: DISCUSSION BY THE BOARD?

3 MS. DURON: DR. STEWARD, THIS IS YSABEL.  
4 MAY I SAY SOMETHING?

5 DR. STEWARD: YES, PLEASE, YSABEL.

6 MS. DURON: THANK YOU. I WAS READING ONE  
7 OF THE APPLICATIONS THAT SCORED IN THE 50S AND 60S.  
8 AND I APPRECIATED THIS FROM ONE OF THE REVIEWERS  
9 WHICH TELLS ME THAT THEY ARE STARTING TO PAY CLOSER  
10 ATTENTION TO THE APPLICATIONS. THEY SAID THEIR  
11 STATEMENT OF INCLUSION DIDN'T REALLY ADDRESS  
12 ANYTHING OTHER THAN TO SAY THEY WOULD INCLUDE  
13 MINORITIES. TO ME THAT IS EXACTLY THE ISSUE, THAT  
14 APPLICANTS ARE NOT BEING -- THEIR FEET ARE NOT BEING  
15 HELD TO THE FIRE ABOUT TAKING THIS ISSUE SERIOUSLY  
16 ABOUT PROPORTIONAL INCLUSION IN THEIR APPLICATIONS.

17 AND I THINK THAT THE MORE WE CAN SEND THAT  
18 MESSAGE BACK, EITHER AS REVIEW NOTES OR AS COMMENTS.  
19 I DON'T KNOW HOW AND IF THE PEOPLE WHOSE  
20 APPLICATIONS DON'T MAKE IT, GET REVIEWS BACK, BUT I  
21 WOULD LIKE THEM TO KNOW THAT THIS IS IMPORTANT AND  
22 THAT THEY CAN'T ANY LONGER CONTINUE TO SLIDE BY  
23 WITHOUT MAKING SURE THAT THEY'VE DONE EVERYTHING  
24 POSSIBLE TO BE SURE THAT THEY'RE LOOKING AT THE  
25 INCLUSION OF RACIAL AND ETHNIC MINORITIES IN THEIR

**BETH C. DRAIN, CA CSR NO. 7152**

1 RESEARCH. WE CANNOT MOVE SCIENCE FORWARD IF WE DO  
2 NOT HAVE A PROPORTIONAL NUMBER OF THESE POPULATIONS  
3 ENGAGED IN RESEARCH. THANK YOU.

4 DR. STEWARD: YES. AND THANK YOU FOR,  
5 AGAIN, RAISING AN IMPORTANT ISSUE AND BRINGING IT TO  
6 OUR ATTENTION. I WILL SAY THAT THE REVIEWERS AT THE  
7 GRANTS WORKING GROUP ARE PAYING CAREFUL ATTENTION TO  
8 THAT, AND WHERE APPROPRIATE THOSE ARE BEING INCLUDED  
9 IN THE REVIEW NOTES WHICH WE, THE BOARD, RECEIVES  
10 AND THEY'RE PUBLIC SUMMARIES.

11 IN ADDITION, COMMENTS OF THIS SORT ARE  
12 GOING INTO THE FULL REVIEWS THAT EACH APPLICANT  
13 RECEIVES. SO THE MESSAGE IS GETTING OUT THERE.  
14 HOPEFULLY QUICKLY, BUT MAYBE NOT AS QUICKLY AS IT  
15 NEEDS TO. SO THANK YOU AGAIN.

16 OTHER COMMENTS BY THE BOARD? SEEING NONE,  
17 ARE THERE PUBLIC COMMENTS?

18 MS. BONNEVILLE: IF THERE ARE MEMBERS OF  
19 THE PUBLIC WHO WOULD LIKE TO SPEAK, IF YOU COULD  
20 PRESS STAR NINE, THAT WILL GIVE YOU ACCESS. I DON'T  
21 SEE ANY, OS.

22 DR. STEWARD: OKAY. HAVING NO PUBLIC  
23 COMMENTS, THEN COULD WE GO AHEAD AND MOVE TO THE  
24 VOTE?

25 MS. BONNEVILLE: ANNE-MARIE DULIEGE.

**BETH C. DRAIN, CA CSR NO. 7152**

1 DR. DULIEGE: YES.  
2 MS. BONNEVILLE: YSABEL DURON.  
3 MS. DURON: YES.  
4 MS. BONNEVILLE: DAVID HIGGINS.  
5 DR. HIGGINS: YES.  
6 MS. BONNEVILLE: STEVE JUELSGAARD.  
7 MR. JUELSGAARD: YES.  
8 MS. BONNEVILLE: DAVE MARTIN. DAVE  
9 MARTIN, I HAVE TO FIND YOU. THERE YOU ARE. THANK  
10 YOU.  
11 DR. MARTIN: (THUMB UP.)  
12 MS. BONNEVILLE: LAUREN MILLER-ROGEN.  
13 MS. MILLER-ROGEN: YES.  
14 MS. BONNEVILLE: JOE PANETTA.  
15 MR. PANETTA: YES.  
16 MS. BONNEVILLE: FRANCISCO PRIETO.  
17 DR. PRIETO: AYE.  
18 MS. BONNEVILLE: ROBERT QUINT.  
19 DR. QUINT: YES.  
20 MS. BONNEVILLE: AL ROWLETT.  
21 MR. ROWLETT: YES.  
22 MS. BONNEVILLE: JEFF SHEEHY.  
23 MR. SHEEHY: YES.  
24 MS. BONNEVILLE: OS STEWARD.  
25 DR. STEWARD: YES.

**BETH C. DRAIN, CA CSR NO. 7152**

1 MS. BONNEVILLE: JONATHAN THOMAS.

2 CHAIRMAN THOMAS: YES.

3 MS. BONNEVILLE: DIANE WINOKUR.

4 MS. WINOKUR: YES.

5 MS. BONNEVILLE: THE MOTION CARRIES.

6 DR. STEWARD: OKAY. THANK YOU, MARIA.

7 NEXT WE'LL MOVE TO THE TWO APPLICATIONS  
8 THAT ARE RECOMMENDED FOR FUNDING. UNLESS THERE ARE  
9 REQUESTS BY MEMBERS OF THE BOARD TO CONSIDER THESE  
10 SEPARATELY, WE MIGHT WANT TO TAKE THEM TOGETHER. IS  
11 THERE A MOTION TO THAT EFFECT OR AN ALTERNATIVE  
12 MOTION?

13 DR. HIGGINS: SO MOVED.

14 DR. STEWARD: DAVID, MAY I INTERPRET THAT  
15 AS A MOTION TO TAKE THEM TOGETHER?

16 DR. HIGGINS: YES. YES. YES. I'M SORRY.  
17 THAT'S EXACTLY WHAT I MEANT.

18 DR. STEWARD: OKAY. THANK YOU. SECOND?

19 MR. ROWLETT: SECOND. THIS IS AL ROWLETT.

20 DR. STEWARD: THANK YOU, AL. DISCUSSION  
21 BY THE BOARD?

22 DR. DULIEGE: YES. ACTUALLY I HAVE A  
23 QUESTION.

24 DR. STEWARD: YES.

25 DR. DULIEGE: JUST A QUICK SCIENTIFIC

**BETH C. DRAIN, CA CSR NO. 7152**

1 QUESTION. CAN I GET A LITTLE BIT OF CLARITY ON  
2 WHETHER THESE TWO APPLICATIONS ARE RELATED FROM A  
3 SCIENTIFIC STANDPOINT? THEY SEEM RELATED TO ME, BUT  
4 I'D LOVE TO HAVE SOME CLARIFICATION.

5 DR. STEWARD: THANK YOU VERY MUCH,  
6 ANNE-MARIE. GIL, CAN YOU SPEAK TO THAT?

7 DR. SAMBRANO: ABSOLUTELY. SO THEY'RE NOT  
8 RELATED IF YOU MEAN COMING FROM THE SAME TEAM,  
9 INVESTIGATOR, OR INSTITUTION.

10 DR. DULIEGE: MORE ABOUT THE SCIENCE  
11 ITSELF.

12 DR. SAMBRANO: OKAY. SO THE DISC1, WHAT  
13 THEY ARE DOING IS THEY ARE DEVELOPING A METHOD.  
14 IT'S KIND OF A CHEMICAL SYNTHESIS APPROACH TO MAKING  
15 SIRNA ABLE TO GO INTO CELLS, GET RELEASED INTO THE  
16 CYTOSOL AND BE EFFECTIVE AGAINST THE VIRUS. SO  
17 THAT'S THE MAIN CORE AND FOCUS OF THAT PROPOSAL.  
18 AND SO PRESUMABLY, IF THAT WORKS, IT REALLY OPENS  
19 THE DOOR TO USING RNAI GENERALLY IN TERMS OF BEING  
20 ABLE TO DELIVER IT TO THE LUNG AND USING THAT AS A  
21 THERAPEUTIC.

22 NOW, THE OTHER DISC2 APPLICATION IS USING  
23 A SOPHISTICATED IPSC-DERIVED LUNG ORGANOID MODEL.  
24 SO THEY'VE DEVELOPED A COMPLEX MODEL THAT INCLUDES  
25 THE VASCULATURE, IT HAS AN IMMUNE COMPARTMENT, AND

**BETH C. DRAIN, CA CSR NO. 7152**

1 REPRESENTS MANY OF THE VARIED CELLS WITHIN THE LUNG.  
2 AND SO THEY'RE USING THAT AS A SCREEN FOR  
3 FDA-APPROVED DRUGS THAT WOULD HAVE AN IMPACT ON THE  
4 INFECTIVITY OF THE LUNG CELLS OR THE LUNG ORGANIDS  
5 BY SARS COV2.

6 AND SO THEY HAVE TWO CANDIDATES THAT THEY  
7 ARE LOOKING AT THAT WENT THROUGH AN INITIAL SCREEN,  
8 AND SO THIS WOULD BE A MORE SOPHISTICATED SCREEN  
9 USING THE LUNG ORGANIDS THAT WOULD ALLOW THEM TO  
10 COLLECT ENOUGH DATA TO TAKE ONE OF THOSE TWO OR  
11 MAYBE BOTH AS CANDIDATES INTO TRANSLATION.

12 DR. DULIEGE: THANK YOU.

13 DR. STEWARD: THANK YOU. OTHER COMMENTS  
14 OR QUESTIONS BY BOARD MEMBERS? SEEING NO HANDS, ARE  
15 THERE ANY COMMENTS FROM MEMBERS OF THE PUBLIC?

16 MS. BONNEVILLE: AGAIN, IF YOU'D LIKE TO  
17 MAKE A COMMENT, PLEASE PRESS STAR NINE. I DON'T SEE  
18 ANY.

19 DR. STEWARD: OKAY. THANK YOU, MARIA. SO  
20 WE'LL GO AHEAD AND CALL THE QUESTION, MARIA.

21 MS. BONNEVILLE: ANNE-MARIE DULIEGE.

22 DR. DULIEGE: YES.

23 MS. BONNEVILLE: YSABEL DURON.

24 MS. DURON: YES.

25 MS. BONNEVILLE: DAVID HIGGINS.

**BETH C. DRAIN, CA CSR NO. 7152**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

DR. HIGGINS: YES.  
MS. BONNEVILLE: STEVE JUELSGAARD.  
MR. JUELSGAARD: YES.  
MS. BONNEVILLE: DAVE MARTIN. OKAY.  
THANK YOU, DAVE.  
DR. MARTIN: (THUMB UP.)  
MS. BONNEVILLE: LAUREN MILLER-ROGEN.  
MS. MILLER-ROGEN: YES.  
MS. BONNEVILLE: ADRIANA PADILLA. JOE  
PANETTA.  
MR. PANETTA: YES.  
MS. BONNEVILLE: FRANCISCO PRIETO.  
DR. PRIETO: AYE.  
MS. BONNEVILLE: ROBERT QUINT.  
DR. QUINT: YES.  
MS. BONNEVILLE: AL ROWLETT.  
MR. ROWLETT: YES.  
MS. BONNEVILLE: JEFF SHEEHY.  
MR. SHEEHY: YES.  
MS. BONNEVILLE: OS STEWARD.  
DR. STEWARD: YES.  
MS. BONNEVILLE: JONATHAN THOMAS.  
CHAIRMAN THOMAS: YES.  
MS. BONNEVILLE: DIANE WINOKUR.  
MS. WINOKUR: YES.

**BETH C. DRAIN, CA CSR NO. 7152**

1 MS. BONNEVILLE: THE MOTION CARRIES.

2 DR. STEWARD: SO THANK YOU. AND THAT  
3 CONCLUDES THE BUSINESS OF THE APPLICATION REVIEW  
4 SUBCOMMITTEE, I BELIEVE, AND PASSING THE GAVEL BACK  
5 TO CHAIRMAN THOMAS.

6 CHAIRMAN THOMAS: THANK YOU VERY MUCH, DR.  
7 STEWARD. AND I BELIEVE, GIL, CORRECT ME IF I'M  
8 WRONG, THOSE WERE COVID AWARDS 15 AND 16 THAT THE  
9 BOARD HAS MADE; IS THAT CORRECT?

10 DR. SAMBRANO: I THINK IT MIGHT BE 14 AND  
11 15, BUT I DON'T HAVE THE NUMBERS IN FRONT OF ME. SO  
12 YOU MIGHT BE CORRECT.

13 CHAIRMAN THOMAS: IN ANY EVENT, I BELIEVE  
14 WE HAVE HAD DISCUSSION WITH THE TEAM, AND WE ARE  
15 ENTERTAINING ONE MORE ROUND OF COVID APPLICATIONS,  
16 WHICH WILL BE HEARD IN PEER REVIEW BY THE GWG ON  
17 JULY 21ST FOR THE BOARD MEETING SUBSEQUENT TO THAT  
18 TO CONSIDER ANY PROJECTS RECOMMENDED FOR FUNDING  
19 THAT COME OUT OF THAT, CORRECT, DR. SAMBRANO?

20 DR. SAMBRANO: CORRECT. YES, THAT'S  
21 RIGHT.

22 CHAIRMAN THOMAS: THANK YOU. AND  
23 CONTINUED THANKS TO YOU AND YOUR TEAM FOR THE EXPERT  
24 HANDLING OF THE APPLICATION PROCESS FOR THESE AND  
25 ALL OTHER GRANTS.

**BETH C. DRAIN, CA CSR NO. 7152**

1 WE ARE NOW AT THE PART OF THE AGENDA FOR  
2 PUBLIC COMMENT FOR ANY TOPIC THAT ANYBODY WANTS TO  
3 SPEAK ABOUT. DO WE HAVE ANY PUBLIC COMMENT AT THIS  
4 TIME? HEARING NONE, THAT WILL CONCLUDE TODAY'S  
5 AGENDA. AND THANK YOU, EVERYBODY, FOR TAKING TIME  
6 ON THIS FRIDAY AFTERNOON. PLEASE CONTINUE TO STAY  
7 SAFE AND HEALTHY, AND WE WILL TALK TO YOU IN TWO  
8 WEEKS. WE STAND ADJOURNED.

9 MS. BONNEVILLE: THANK YOU, EVERYONE.  
10 (THE MEETING WAS THEN CONCLUDED AT 3:31 P.M.)

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

**REPORTER'S CERTIFICATE**

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE ZOOM PROCEEDINGS BEFORE THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE AND THE APPLICATION REVIEW SUBCOMMITTEE IN THE MATTER OF ITS EMERGENCY MEETING HELD ON JULY 10, 2020, WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CA CSR 7152  
133 HENNA COURT  
SANDPOINT, IDAHO  
(208) 255-5453